Elsevier

Atherosclerosis

Volume 217, Issue 1, July 2011, Pages 3-46
Atherosclerosis

Review
ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS),☆☆

Developed with the special contribution of: European Association for Cardiovascular Prevention & Rehabilitation.
https://doi.org/10.1016/j.atherosclerosis.2011.06.028

Abbreviations

4D Die
Deutsche Diabetes Dialyse Studie
4S
Scandinavian Simvastatin Survival Study
ABC-1
ATP-binding cassette transporter 1
ACCORD
Action to Control Cardiovascular Risk in Diabetes
ACS
acute coronary syndrome
AIM-HIGH
Atherothrombosis Intervention in Metabolic syndrome with Low HDL-C/High Triglyceride and Impact on Global Health Outcomes
ALT
alanine aminotransferase
apo (a)
apolipoprotein (a)
apo A1
apolipoprotein A1
apo B
apolipoprotein B
apo E
apolipoprotein E
apo C
apolipoprotein C
ARBITER-6 HALTS
Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6: HDL and LDL Treatment Strategies in Atherosclerosis
ARMYDA
Atorvastatin for Reduction of Myocardial Damage During Angioplasty
ASSIGN
CV risk estimation model from the Scottish Intercollegiate Guidelines Network
AURORA
A study to evaluate the Use of Rosuvastatin in subjects On Regular haemodialysis: an Assessment of survival and cardiovascular events
BIP
Bezafibrate Infarction Prevention
BMI
body mass index
CABG
coronary artery bypass graft
CAD
coronary artery disease
CARE
Cholesterol and Recurrent Events
CETP
cholesterylester transfer protein
CI
confidence interval
CIMT
carotid intima–media thickness
CK
creatine phosphokinase
CKD
chronic kidney disease
CORONA
Controlled ROsuvastatin multiNAtional study in heart failure
CPG
ESC Committee for Practice Guidelines
CTT
Cholesterol Treatment Trialists’ Collaboration
CV
cardiovascular
CVD
cardiovascular disease
CYP
cytochrome P450 isoenzyme
Dal-OUTCOMES
Dalcetrapib Outcomes trial
DALYs
disability-adjusted life years
DHA
docosahexaenoid acid
DGAT-2
diacylglycerol acyltransferase-2
EAS
European Atherosclerosis Society
EMEA
European Medicines Agency
EPA
eicosapentaenoic acid
ER
extended release form
ESC
European Society of Cardiology
ESRD
end-stage renal disease
FATS
Familial Atherosclerosis Treatment Study
FCH
familial combined hyperlipidaemia
FDA
Food and Drug Administration
FH
familial hypercholesterolaemia
FIELD
Fenofibrate Intervention and Event Lowering in Diabetes
GFR
glomerular filtration rate
GISSI-HF
Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico-Effect of rosuvastatin in patients with chronic Heart Failure
GISSI-P
Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico-Prevenzione
GP
general practitioner
GPR
G protein-coupled receptor
HAART
highly active antiretroviral treatment
HATS
HDL-Atherosclerosis Treatment Study
HbA1c
glycated haemoglobin
HDL
high-density lipoprotein
HDL-C
high-density lipoprotein-cholesterol
HeFH
heterozygous familial hypercholesterolaemia
HF
heart failure
HHS
Helsinki Heart Study
HIV
human immunodeficiency virus
HMG-CoA
hydroxymethylglutaryl coenzyme A
HoFH
homozygous familial hypercholesterolaemia
HPS
Heart Protection Study
HPS2-THRIVE
Heart Protection Study 2 Treatment of HDL to Reduce the Incidence of Vascular Events
hs-CRP
high sensitivity C-reactive protein
HTG
hypertriglyceridaemia
ICD
International Classification of Diseases
IDL
intermediate-density lipoprotein
ILLUMINATE
Investigation of Lipid Levels Management to Understand its Impact in Atherosclerotic Events
JUPITER
Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin Study
LCAT
lecithin-cholesterol acyltransferase
LDL
low-density lipoprotein
LDLR
low-density lipoprotein receptor
LDL-C
low-density lipoprotein-cholesterol
Lp(a)
lipoprotein(a)
LPL
lipoprotein lipase
MetS
metabolic syndrome
MI
myocardial infarction
MTP
microsomal transfer protein
MUFA
monounsaturated fatty acid
NICE
National Institute for Health and Clinical Excellence
NNT
number needed to treat
Non-HDL-C
non-HDL-cholesterol
NYHA
New York Heart Association
PAD
peripheral arterial disease
PCI
percutaneous coronary intervention
PCSK9
proprotein convertase subtilisin/Kexin 9
PPAR
peroxisome proliferator-activated receptor
PPP
Pravastatin Pooling Project
PROCAM
Prospective Cardiovascular Munster study
PROSPER
Prospective Study of Pravastatin in the Elderly at Risk
PROVE-IT
Pravastatin or Atorvastatin Evaluation and Infection Therapy
PUFA
polyunsaturated fatty acid
RAAS
system renin–angiotensin–aldosterone system
RCT
randomized controlled trial
REVEAL
Randomized Evaluation of the Effects of Anacetrapib Through Lipid-modification
RRR
relative risk reduction
RYR
red yeast rice
SCORE
Systematic Coronary Risk Estimation
SEAS
Simvastatin and Ezetimibe in Aortic Stenosis
SFA
saturated fatty acids
SHARP
Study of Heart And Renal Protection
SLE
systemic lupus erythematosus
TC
total cholesterol
TG
triglycerides
TIA
transient ischaemic attack
TNT
Treating to New Targets Trial
TRL
triglyceride-rich lipoprotein
ULN
upper limit of normal
USF 1
upstream transcription factor 1
VA-HIT
Veterans Affairs High-density lipoprotein Intervention Trial
VLDL
very low density lipoprotein
VLDL-C
very low density lipoprotein-cholesterol
WHO
World Health Organization

Keywords

Dyslipidaemia
Cholesterol
Triglycerides
Treatment
Cardiovascular diseases
Guidelines

Cited by (0)

Disclaimer: The ESC Guidelines represent the views of the ESC and the EAS, and were arrived at after careful consideration of the available evidence at the time they were written. Health professionals are encouraged to take them fully into account when exercising their clinical judgement. The guidelines do not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patients, in consultation with that patient, and where appropriate and necessary the patient's guardian or carer. It is also the health professional's responsibility to verify the rules and regulations applicable to drugs and devices at the time of prescription.

☆☆

The disclosure forms of the authors and reviewers are available on the ESC website www.escardio.org/guidelines.

Other ESC entities having participated in the development of this document: Associations: Heart Failure Association. Working Groups: Cardiovascular Pharmacology and Drug Therapy, Hypertension and the Heart, Thrombosis. Councils: Cardiology Practice, Primary Cardiovascular Care, Cardiovascular Imaging. The content of these European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to Oxford University Press, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC.

View Abstract